Tetra Bio-Pharma Provides Additional Information on QIXLEEF Following Letter of Advice & Type B Meeting with USA FDA
QIXLEEF global market is expanded to include noncancer pain indications.OTTAWA, Feb. 24, 2020 (GLOBE NEWSWIRE) — Tetra Bio-Pharma Inc. (“Tetra” […]